Efficacy and Safety of Secukinumab in Chronic Plaque Psoriasis and Psoriatic Arthritis Therapy

Dermatology and Therapy

Volumn 4, Issue 1, 2014, Pages 1-9

  Gisondi, Paolo ^a   Dalle Vedove, Camilla ^a   Girolomoni, Giampiero ^a  

^a UNIVERSITY OF VERONA   (Italy)

Author keywords

Brodalumab; Chronic plaque psoriasis; Dermatology; Ixekizumab; Psoriasis; Psoriatic arthritis; Secukinumab

Indexed keywords

BRODALUMAB; ETANERCEPT; INTERLEUKIN 17; IXEKIZUMAB; PLACEBO; SECUKINUMAB; TUMOR NECROSIS FACTOR ALPHA;

CHRONIC DISEASE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; HEADACHE; HUMAN; INJECTION SITE ERYTHEMA; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RHINOPHARYNGITIS; UPPER RESPIRATORY TRACT INFECTION;

EID: 84902177664     PISSN: 21938210     EISSN: 21909172     Source Type: Journal    
DOI: 10.1007/s13555-014-0042-5     Document Type: Review

References (37)

1. Jacobson CC, Kumar S, Kimball AB. Latitude and psoriasis prevalence. J Am Acad Dermatol. 2011;65:870–3.
2. Gisondi P, Tessari G, Conti A, et al. Prevalence of metabolic syndrome in patients with psoriasis: a hospital-based case–control study. Br J Dermatol. 2007;157:68–73.
3. Gisondi P, Targher G, Zoppini G, et al. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758–64.
4. Gisondi P, Targher G, Cagalli A, Girolomoni G. Hyperuricaemia in patients with chronic plaque psoriasis. J Am Acad Dermatol. 2014;70:127–30.
5. Lu Y, Chen H, Nikamo P, et al. Association of cardiovascular and metabolic disease genes with psoriasis. J Invest Dermatol. 2013;133:836–9.
6. Suárez-Fariñas M, Li K, Fuentes-Duculan J, Hayden K, Brodmerkel C, Krueger JG. Expanding the psoriasis disease profile: interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012;132:2552–64.
7. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med. 2009;361:496–509.
8. Albanesi C, Scarponi C, Pallotta S, et al. Chemerin expression marks early psoriatic skin lesions and correlates with plasmacytoid dendritic cell recruitment. J Exp Med. 2009;206:249–58.
9. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128:1207–11.
10. Ruddy MJ, Wong GC, Liu XK, et al. Functional cooperation between interleukin-17 and tumor necrosis factor-alpha is mediated by CCAAT/enhancer-binding protein family members. J Biol Chem. 2004;27:2559–67.
11. Girolomoni G, Mrowietz U, Paul C. Psoriasis: rationale for targeting interleukin-17. Br J Dermatol. 2012;167:717–24.
12. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nat Rev Immunol. 2009;9:556–67.
13. Chiricozzi A, Krueger JG. IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs. 2013;22:993–1005.
14. Rizzo HL, Kagami S, Phillips KG, et al. IL-23-mediated psoriasis-like epidermal hyperplasia is dependent on IL-17A. J Immunol. 2011;186:1495–502.
15. Hueber W, Patel DD, Dryja T et al. Effects of AIN457, a fully human antibody to interleukin-17A, on psoriasis, rheumatoid arthritis, and uveitis. Sci Transl Med. 2010;2:52–72.
16. Papp KA, Langley RG, Sigurgeirsson B, et al. Secukinumab efficacy and safety preliminary results from a phase II subcutaneous dose-ranging study in the treatment of moderate-to-severe plaque psoriasis. Br J Dermatol. 2013;168:412–21.
17. Rich P, Sigurgeirsson B, Thaci D, et al. Secukinumab induction and maintenance therapy in moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled, phase II regimen-finding study. Br J Dermatol. 2013;168:402–11.
18. Papp KA, Matheson RT, Tu JH et al. Secukinumab, a novel fully human antibody to interleukin-17A, in the treatment of moderate-to-severe plaque psoriasis: efficacy and safety interim results from a phase II intravenous induction dose-ranging study. Presented at: 20th congress of the European Academy of Dermatology and Venereology; 20–24 October 2011, Lisbon, Portugal. Abstract 0630.
19. Clinicaltrials.gov. http://www.clinicaltrials.gov/ct2/results?term=secukinumab+AND+psoriasis. Accessed December 13, 2013.
20. McInnes IB, Sieper J, Braun J, et al. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial. Ann Rheum Dis. 2014;73:349–56.
21. Kelly MN, Kolls JK, Happel K, et al. Interleukin-17/interleukin-17 receptor-mediated signaling is important for generation of an optimal polymorphonuclear response against Toxoplasma gondii infection. Infect Immun. 2005;73:617–21.
22. Huang W, Na L, Fidel PL, Schwarzenberger P. Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J Infect Dis. 2004;190:624–31.
23. Happel KI, Zheng M, Young E, et al. Cutting edge: roles of Toll-like receptor 4 and IL-23 in IL-17 expression in response to Klebsiella pneumoniae infection. J Immunol. 2003;170:4432–6.
24. Puel A, Cypowyj S, Bustamante J, et al. Chronic muco-cutaneous candidiasis in humans with inborn errors of interleukin-17 immunity. Science. 2011;332:65–8.
25. Lebwohl M, Bagel J, Gelfand JM, et al. From the Medical Board of the National Psoriasis Foundation: monitoring and vaccinations in patients treated with biologics for psoriasis. J Am Acad Dermatol. 2008;58:94–105.
26. Kaine JL, Kivitz AJ, Birbara C, et al. Immune responses following administration of influenza and pneumococcal vaccines to patients with rheumatoid arthritis receiving adalimumab. J Rheumatol. 2007;34:272–9.
27. Oren S, Mandelboim M, Braun-Moscovici Y, et al. Vaccination against influenza in patients with rheumatoid arthritis: the effect of rituximab on the humoral response. Ann Rheum Dis. 2008;67:937–41.
28. Chioato A, Noseda E, Stevens M, et al. Treatment with the interleukin-17A-blocking antibody secukinumab does not interfere with the efficacy of influenza and meningococcal vaccinations in healthy subjects: results of an open label, parallel-group, randomized single-center study. Clin Vaccine Immunol. 2012;19:1597–602.
29. Leonardi C, Matheson R, Zachariae C, et al. Anti-interleukin-17 monoclonal antibody ixekizumab in chronic plaque psoriasis. N Engl J Med. 2012;366:1190–9.
30. Clinicatrials.gov. http://www.clinicaltrials.gov/ct2/results?term=ixekizumab+AND+psoriasis. Accessed December 13, 2013.
31. Reichert JM. Which are the antibodies to watch in 2013? mAbs. 2013;5:1–4.
32. Russell CB, Kerkof K, Bigler J, et al. Blockade of the IL-17R with AMG827 leads to rapid reversal of gene expression and histopathologic abnormalities in human psoriatic skin. J Invest Dermatol. 2010;130:S46.
33. Papp KA, Leonardi C, Menter A, et al. Brodalumab, an anti-interleukin- 17-receptor antibody for psoriasis. N Engl J Med. 2012;366:1181–9.
34. Esposito M, Gisondi P, Cassano N, et al. Survival rate of anti-TNF alpha treatments for psoriasis in routine dermatological practice: a multicenter observational study. Br J Dermatol. 2013;. doi:10.1111/bjd.12422.
35. Talamonti M, Botti E, Galluzzo M, et al. Pharmacogenetics of psoriasis: HLA-Cw6 but not LCE3B/3C deletion nor TNFAIP3 polymorphism predisposes to clinical response to interleukin 12/23 blocker ustekinumab. Br J Dermatol. 2013;169:458–63.
36. Tejasvi T, Stuart PE, Chandran V, et al. TNFAIP3 gene polymorphisms are associated with response to TNF blockade in psoriasis. J Invest Dermatol. 2012;132(3 Pt 1):593–600.
37. Chen S, Crother TR, Arditi M. Emerging role of IL-17 in atherosclerosis. J Innate Immun. 2010;2:325–33.